COVA208

COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive breast cancer, gastric cancer, and colorectal cancer[1].

12352203

Akt; EGFR; p38 MAPK; PI3K

JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Cancer-Kinase/protease

Cancer

O=C([A208])[V]

[1]Brack S, et al. A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action. Mol Cancer Ther. 2014 Aug;13 (8) :2030-9.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991234/

Inhibitory Antibodies

No Development Reported

ErbB2/HER2